Cargando…

1822. Clinical Outcomes Associated with Oral Beta-Lactam Therapy versus Oral Fluoroquinolones/TMP-SMX for Uncomplicated Gram-Negative Bacteremia

BACKGROUND: Agents commonly used as oral step-down therapy in Enterobacterales bacteremia include fluoroquinolones and TMP-SMX. The use of these oral agents have been associated with adverse events. Oral β-lactams are not recommended to treat Enterobacterales bacteremia because of concerns for sub-t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaur, Satwinder S, Babic, Jessica T, Nguyen, Steven, Patel, Shivani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981864/ http://dx.doi.org/10.1093/ofid/ofac492.1452

Ejemplares similares

210. Step-down from IV to oral therapy in patients with bacteremia due to Enterobacteriaceae: fluoroquinolones (FQ) vs. ß-lactams (BL) or trimethoprim-sulfamethoxazole (TMP-SMX)
por: Meng, Lina, et al.
Publicado: (2019)

271. Clinical Outcomes Treating Gram-Negative Bacteremia with Oral Beta-Lactams vs. Trimethoprim-Sulfamethoxazole or Fluoroquinolone Step-Down Therapy
por: Sinclair, Emily, et al.
Publicado: (2020)

TMP-SMX induced type 4 hypersensitivity with multi-organ involvement
por: Sircar, Samantha, et al.
Publicado: (2023)

277. Comparison of Oral Beta-Lactams and Fluoroquinolones for Step-Down in Uncomplicated Enterobacterales Blood Stream Infections
por: Ngo, Nichol, et al.
Publicado: (2020)

1022. Is it Time to Re-Evaluate Oral Β-Lactam Antibiotics for Step-Down Therapy of Uncomplicated Gram-Negative Bacteremia?
por: McAlister, Michael, et al.
Publicado: (2019)

1072. Streamlining to Oral β-Lactam vs. Fluoroquinolone as Definitive Therapy for Enterobacteriaceae Bacteremia
por: Fong, Karen, et al.
Publicado: (2018)

Antibody- Based Immunotherapy Combined With Antimycotic Drug TMP- SMX to Treat Infection With Paracoccidioides brasiliensis
por: Boniche-Alfaro, Camila, et al.
Publicado: (2021)

Low-Dose TMP-SMX in the Treatment of Pneumocystis jirovecii Pneumonia: A Systematic Review and Meta-analysis
por: Butler-Laporte, Guillaume, et al.
Publicado: (2020)

1304. Antimicrobial Management of Stenotrophomonas maltophilia Pneumonia: Does TMP-SMX Dose Affect Treatment Failure?
por: Keck, J Myles, et al.
Publicado: (2021)

Outcomes of high-dose oral beta-lactam definitive therapy compared to fluoroquinolone or trimethoprim-sulfamethoxazole oral therapy for bacteremia secondary to a urinary tract infection
por: Geyer, Abigail C., et al.
Publicado: (2023)

Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy
por: Li, Cong, et al.
Publicado: (2020)

219. Outcomes with Low- vs. High-bioavailability Oral Antibiotics in Treatment of Uncomplicated Gram-Negative Bacteremia
por: Cubillos, Ashley L, et al.
Publicado: (2021)

258. A Comparison of Cefprozil and Fluoroquinolones for Gram-Negative Bacteremia
por: Nolen, Rebecca C, et al.
Publicado: (2020)

219. Clinical Outcomes of Early vs Late Oral Stepdown Therapy in the Management of Uncomplicated Gram-Negative Bacteremia
por: Michael, Amanda, et al.
Publicado: (2023)

Impact of an Antimicrobial Stewardship Bundle for Uncomplicated Gram-Negative Bacteremia
por: Erickson, Reaghan M, et al.
Publicado: (2019)

Oral β-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source
por: Sutton, Jesse D., et al.
Publicado: (2020)

Oral Fluoroquinolone or Trimethoprim-Sulfamethoxazole vs ß-Lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis
por: Punjabi, Chitra, et al.
Publicado: (2019)

Clinical Outcomes With Extended Versus Intermittent Infusion of Anti-Pseudomonal Beta-Lactams in Patients With Gram-Negative Bacteremia
por: Tran, Nikki N, et al.
Publicado: (2023)

Correction to: Clinical Outcomes With Extended Versus Intermittent Infusion of Anti-Pseudomonal Beta-Lactams in Patients With Gram-Negative Bacteremia
Publicado: (2023)

149. Short vs. Long Course of Antibiotics for Uncomplicated Gram-Negative Bacteremia
por: Go, James, et al.
Publicado: (2019)

2545. Impact of Early Dose Adjustment of Beta-Lactams in Patient with Septic Shock
por: Tawwater, John C, et al.
Publicado: (2023)

1842. Intravenous to Oral Antibiotic Stepdown for Uncomplicated Streptococcal Bacteremia
por: Salam, Madison E, et al.
Publicado: (2022)

222. Oral Step-Down Therapy for Uncomplicated Enterococcus Bacteremia
por: Ni, Jessica, et al.
Publicado: (2023)

1459. Oral Cephalosporins vs. Fluoroquinolones for the Empiric Treatment of Acute Uncomplicated Pyelonephritis
por: Lin, Kevin, et al.
Publicado: (2019)

278. Comparison of Oral Cephalexin Versus Oral Levofloxacin for Treatment of Uncomplicated Enterobacterales Bacteremia
por: Leung, Thomas H, et al.
Publicado: (2020)

Challenges to Early Discharge of Patients with Upper Urinary Tract Infections by ESBL Producers: TMP/SMX as a Step-Down Therapy for Shorter Hospitalization and Lower Costs
por: Shi, Hye Jin, et al.
Publicado: (2021)

1882. Resistance (R) Trends in Gram-Negative Bacilli (GNB) to Fluoroquinolones (FQ), [Ciprofloxacin (CIP), Levofloxacin (LEV), Moxifloxacin (MOX)], Trimethoprim–Sulfamethoxazole (TMP/SMX) and Nitrofurantoin (NFT) over a 7-Year Period: Pre- and Post-Implementation of FQ Restriction at a Tertiary Care Veterans Affairs Medical Center (VAMC)
por: Natesan, Suganthini Krishnan, et al.
Publicado: (2018)

Comparative-Effectiveness of Oral Beta-Lactams and Fluoroquinolones for Stepdown Therapy in Patients with Enterobacterales Bloodstream Infections: A Retrospective Cohort Study
por: Bjork, Lauren, et al.
Publicado: (2023)

166. Comparison of Oral Fluoroquinolones to Alternative Oral Agents for Definitive Step-Down Therapy in Gram-Negative Bloodstream Infections
por: Cho, Christian Y, et al.
Publicado: (2019)

SMX makes the cut in genome stability
por: Wyatt, Haley D.M., et al.
Publicado: (2017)

The SMX DNA Repair Tri-nuclease
por: Wyatt, Haley D.M., et al.
Publicado: (2017)

Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01
por: Pratoomwun, Jirawat, et al.
Publicado: (2021)

Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives
por: Garcia-Bustos, Víctor, et al.
Publicado: (2022)

52. Development and Implementation of a Short Duration of Antibiotic Therapy Algorithm for Uncomplicated Gram-Negative Bacteremia
por: Bae, Esther Y, et al.
Publicado: (2020)

165. Comparative Effectiveness of Oral Fluoroquinolones vs. β-Lactams for the Treatment of Patients with Enterobacteriaceae Bloodstream Infections
por: Bjork, Lauren, et al.
Publicado: (2019)

Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy
por: FakhriRavari, Alireza, et al.
Publicado: (2022)

Predicting Oral Beta-lactam susceptibilities against Streptococcus pneumoniae
por: Murphy, Mark E., et al.
Publicado: (2021)

Fluoroquinolone and beta-lactam antimicrobials induce different transcriptome profiles in Salmonella enterica persister cells
por: Mattiello, S. P., et al.
Publicado: (2023)

656. Prioritizing Gram-Negative Bacteremia (GNB) Cases for Rapid Detection by β-Lactam Resistance (BLR) and Patient Outcomes
por: McCreary, Erin K, et al.
Publicado: (2019)

Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs
por: Connelly, Sheila, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c4qq43aroihhegpcp3ikp2mu1r